The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
Open accessAbstract
Histone deacetylases (HDACs) represent novel molecular targets for the treatment of various types of cancers, including multiple myeloma (MM). Many HDAC inhibitors have already shown remarkable antitumor activities in the preclinical setting; however, their clinical utility is limited because of unfavorable toxicities associated with their broad range HDAC inhibitory effects. Isoform-selective HDAC inhibition may allow for MM cytotoxicity without attendant side effects. In this study, we demonstrated that HDAC3 knockdown and a small-molecule HDAC3 inhibitor BG45 trigger significant MM cell growth inhibition via apoptosis, evidenced by caspase and poly (ADP-ribose) polymerase cleavage. Importantly, HDAC3 inhibition downregulates phosphorylation (tyrosine 705 and serine 727) of signal transducers and activators of transcription 3 (STAT3). Neither interleukin-6 nor bone marrow stromal cells overcome this inhibitory effect of HDAC3 inhibition on phospho-STAT3 and MM cell growth. Moreover, HDAC3 inhibition also triggers hyperacetylation of STAT3, suggesting crosstalk signaling between phosphorylation and acetylation of STAT3. Importantly, inhibition of HDAC3, but not HDAC1 or 2, significantly enhances bortezomib-induced cytotoxicity. Finally, we confirm that BG45 alone and in combination with bortezomib trigger significant tumor growth inhibition in vivo in a murine xenograft model of human MM. Our results indicate that HDAC3 represents a promising therapeutic target, and validate a prototype novel HDAC3 inhibitor BG45 in MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, an example of the importance of the cap group is highlighted in mocetinostat (Figure 10), where selectivity is gained for HDAC1/2 against HDAC3 (5.5–10.7 fold selective) without resorting to the use of an FT substituent [64].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [64]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
Self-citationHistone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 893
Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue
Yuan, Z.-L., Guan, Y.-J., Chatterjee, D., & Chin, Y. E. (2005) · Science · doi:10.1126/science.1105166 · Cited by 790
Chemical phylogenetics of histone deacetylases
Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720
Self-citationSanto, L., Hideshima, T., Kung, A. L., Tseng, J.-C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J. H., Mazitschek, R., Ogier, W. C., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387365 · Cited by 616
Self-citationHideshima, T., Bradner, J. E., Wong, J. Y. Y., Chauhan, D., Richardson, P. G. G., Schreiber, S. L., & Anderson, K. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503221102 · Cited by 603
Self-citationHideshima, T., Catley, L. P., Yasui, H., Ishitsuka, K., Raje, N. S., Mitsiades, C. S., Podar, K., Munshi, N. C., Chauhan, D., Richardson, P. G. G., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3434 · Cited by 423
Self-citationMolecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature reviews. Cancer · doi:10.1038/nrc952 · Cited by 417
Self-citationCatley, L. P., Weisberg, E., Kiziltepe, T., Tai, Y., Hideshima, T., Neri, P., Tassone, P., Atadja, P. W., Chauhan, D., Munshi, N. C., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016055 · Cited by 336
Self-citationNonhistone protein acetylation as cancer therapy targets
Singh, B. N., Zhang, G., Hwa, Y. L., Li, J., Dowdy, S. C., & Jiang, S. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.62 · Cited by 315
Flagged first, then by citations
Research works printed but not linked: 1
- Raje N, Mahindra A, Vogl D, Voorhees P, W B, Hari P et al. New drug partner for combination therapy in multiple myeloma (MM): development of ACY-1215, a selective histone deacetylase 6 inhibitor alone and in combination with bortezomib or lenalidomide. Haematologica 2013; 98: 320.
Cited by
Sorted by citations
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
HDACs and HDAC Inhibitors in Cancer Development and TherapyPreprint
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,337
Targeting Class I Histone Deacetylases in a “Complex” Environment
Millard, C. J., Watson, P. J., Fairall, L., & Schwabe, J. W. R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.006 · Cited by 180
Improving target assessment in biomedical research: the GOT-IT recommendations
Emmerich, C. H., Martinez‐Gamboa, L., Hofmann, M. C. J., Bonin, M., Arbach, O., Schendel, P., Gerlach, B., Hempel, K., Bespalov, A., Dirnagl, U., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0087-3 · Cited by 243
Tao, G., Dingfei, Q., Li, L., Xiaowei, W., Zhou, Z., Liu, W., Zhu, T., Ning, B., Yan-ning, Q., Wei, Z., et al. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00333-8 · Cited by 154
Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review
Sarkar, R., Banerjee, S., Amin, S. A., Adhikari, N., & Jha, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112171 · Cited by 121
The application of histone deacetylases inhibitors in glioblastoma
Chen, R., Zhang, M., Zhou, Y., Guo, W., Yi, M., Zhang, Z., Ding, Y., & Wang, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01643-6 · Cited by 127
Zhao, W., Qin, P., Zhang, D., Cui, X., Gao, J., Yu, Z., Chai, Y., Wang, J., & Li, J. (2019) · Aging · doi:10.18632/aging.102406 · Cited by 115
“A study conducted by Ho et al [25] suggested that the HDAC3 inhibitor overcomes the anti-apoptotic effect of BMSCs to multiple myeloma cells.”
The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy
Yang, Y., Zhang, M., & Wang, Y. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.09.002 · Cited by 140
“Except the functions of HDAC1/2 mentioned above, HDAC3 is much more important in MM. Inhibition of HDAC3 induced a stronger decrease in MM cell growth than inhibition of HDAC1 and HDAC2, indicating that HDAC3 is a more attractive target in MM 150 .”
BackgroundRecent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
Cappellacci, L., Perinelli, D. R., Maggi, F., Grifantini, M., & Petrelli, R. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181016163110 · Cited by 141
Novel therapeutic strategies for multiple myeloma
Mimura, N., Hideshima, T., & Anderson, K. C. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.04.010 · Cited by 110
“have shown that an HDAC3-selective inhibitor BG45, alone and in combination with bortezomib, triggers significant anti-MM activities both in vitro and in vivo [112].”
BackgroundSelf-citationLanka, G., Begum, D., Banerjee, S., Adhikari, N., Yogeeswari, P., & Ghosh, B. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107481 · Cited by 107
Self-citationPromising therapies in multiple myeloma
Bianchi, G., Richardson, P. G. G., & Anderson, K. C. (2015) · Blood · doi:10.1182/blood-2015-03-575365 · Cited by 86
“For example, HDAC3 knockdown triggers MM cytotoxicity and apoptosis, and HDAC3 selective inhibitor BG45 is active, alone or with bortezomib, in MM preclinical models.(50) Thus, isoform-selective oral HDACIs may improve tolerability, allowing for their future clinical evaluation in combination with targeted and immune…”
BackgroundSelf-citationShan, X., Fu, Y.-S., Aziz, F., Wang, X.-Q., Yan, Q., & Liu, J.-W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115401 · Cited by 104
European Perspective on Multiple Myeloma Treatment Strategies in 2014
Ludwig, H., Sonneveld, P., Davies, F. E., Bladé, J., Boccadoro, M., Cavo, M., Morgan, G. J., de la Rubia, J., Delforge, M., Dimopoulos, M. A., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0042 · Cited by 102
HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
Harada, T., Ohguchi, H., Grondin, Y., Kikuchi, S., Sagawa, M., Tai, Y.-T., Mazitschek, R., Hideshima, T., & Anderson, K. C. (2017) · Leukemia · doi:10.1038/leu.2017.144 · Cited by 89
Development and classes of epigenetic drugs for cancer
Dhanak, D., & Jackson, P. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.006 · Cited by 83
Long, J., Fang, W. Y., Chang, L., Gao, W. H., Shen, Y., Jia, M. Y., Zhang, Y. X., Wang, Y., Dou, H. B., Zhang, W. J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.130 · Cited by 78
Clinical advances in targeting epigenetics for cancer therapy
Feng, S., & Carvalho, D. D. D. (2021) · FEBS Journal · doi:10.1111/febs.15750 · Cited by 109
Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma
Issa, M. E., Takhsha, F. S., Chirumamilla, C. S., Perez-Novo, C. A., Berghe, W. V., & Cuendet, M. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0319-5 · Cited by 79
“cytotoxicity in vitro, and triggered tumor growth inhibition in a murine xenograft model of human MM, suggesting that HDAC3 represents a promising therapeutic target for the treatment of MM [141].”
BackgroundWu, H., Medeiros, L. J., & Young, K. H. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.08.004 · Cited by 80
Tanaka, H., Muto, A., Shima, H., Katoh, Y., Sax, N., Tajima, S., Brydun, A., Ikura, T., Yoshizawa-Sugata, N., Masai, H., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.713842 · Cited by 80
“Recently, HDAC3 has been reported as a new therapeutic target of multiple myeloma (39).”
BackgroundEmerging approaches for histone deacetylase inhibitor drug discovery
Zwergel, C., Valente, S., Jacob, C., & Mai, A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1038236 · Cited by 77
The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
Cao, F., Zwinderman, M., & Dekker, F. (2018) · Molecules · doi:10.3390/molecules23030551 · Cited by 66
Adhikari, N., Jha, T., & Ghosh, B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01676 · Cited by 74
Self-citationSmalley, J. P., Baker, I. M., Pytel, W. A., Lin, L., Bowman, K. J., Schwabe, J. W. R., Cowley, S. M., & Hodgkinson, J. T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02179 · Cited by 84
“The remaining fluorine-functionalized molecules 14 and 16 exhibited no gains in HDAC3 selectivity, with the PEG linker 16 exhibiting only modest HDAC3 degradation at 10 μ M. Compounds 14 − 17 did not increase H3K56ac to the same levels as 1 or CI-994, with only 17 exhibiting a greater than twofold…”
Histone deacetylase inhibitors in multiple myeloma: from bench to bedside
Harada, T., Hideshima, T., & Anderson, K. C. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2008-0 · Cited by 59
Self-citationHideshima, T., Cottini, F., Ohguchi, H., Jakubı́ková, J., Görgün, G., Mimura, N., Tai, Y., Munshi, N. C., Richardson, P. G. G., & Anderson, K. C. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.38 · Cited by 65
Self-citationAdhikari, N., Amin, S. A., Trivedi, P., Jha, T., & Ghosh, B. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.081 · Cited by 77
Self-citationVallabhapurapu, S., Noothi, S. K., Pullum, D. A., Lawrie, C. H., Pallapati, R. R., Potluri, V., Kuntzen, C., Khan, S., Plas, D. R., Orlowski, R. Z., et al. (2015) · Nature Communications · doi:10.1038/ncomms9428 · Cited by 65
Chen, J., Li, N., Liu, B., Ling, J., Yang, W., Pang, X., & Li, T. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117469 · Cited by 66
Pulya, S., Himaja, A., Paul, M., Adhikari, N., Banerjee, S., Routholla, G., Biswas, S., Jha, T., & Ghosh, B. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00614 · Cited by 63
Self-citationMarson, C. M., Matthews, C. J., Atkinson, S. J., Lamadema, N., & Thomas, N. S. B. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00545 · Cited by 58
Wang, H., Liu, Y.-C., Zhu, C.-Y., Yan, F., Wang, M.-Z., Chen, X., Wang, X.-K., Pang, B., Li, Y.-H., Liu, D.-H., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01792-8 · Cited by 57
Trivedi, P., Adhikari, N., Amin, S. A., Jha, T., & Ghosh, B. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.08.030 · Cited by 65
“Moreover, it was also found to be effective in vivo in arresting tumor growth as evidenced in the murine xenograft model of multiple myeloma (Minami et al., 2014).”
BackgroundSelf-citationIbrahim, H. S., Abdelsalam, M., Zeyn, Y., Zessin, M., Mustafa, A.-H. M., Fischer, M. A., Zeyen, P., Sun, P., Bülbül, E. F., Vecchio, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010369 · Cited by 50
“The HDAC1 (PDB ID: 4BKX) in apo-form and HDAC3 (PDB ID: 4A69) in apo-form were minimized with the ligand of HDAC2 (PDB ID: 4LY1) and BG45 molecules [59], respectively.”
BackgroundProgrammed cell death 5 mediates HDAC3 decay to promote genotoxic stress response
Choi, H.-K., Choi, Y., Park, E. S., Park, S., Lee, S., Seo, J., Jeong, M., Jeong, J., Cheong, J., Lee, P. C.-W., et al. (2015) · Nature Communications · doi:10.1038/ncomms8390 · Cited by 57
Peng, X., Chen, J., Li, L., Sun, Z., Liu, J., Ren, Y., Huang, J., & Chen, J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00413 · Cited by 71
Epigenetic Aberrations in Multiple Myeloma
Caprio, C., Sacco, A., Giustini, V., & Roccaro, A. M. (2020) · Cancers · doi:10.3390/cancers12102996 · Cited by 49
Pulya, S., Patel, T. K., Paul, M., Adhikari, N., Banerjee, S., Routholla, G., Biswas, S., Jha, T., & Ghosh, B. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114470 · Cited by 55
Self-citationThe biological significance of histone modifiers in multiple myeloma: clinical applications
Ohguchi, H., Hideshima, T., & Anderson, K. C. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0119-y · Cited by 47
Self-citationIaconelli, J., Huang, J., Berkovitch, S. S., Chattopadhyay, S., Mazitschek, R., Schreiber, S. L., Haggarty, S. J., & Karmacharya, R. (2014) · ACS Chemical Biology · doi:10.1021/cb500838r · Cited by 45
Self-citationChidamide: Targeting epigenetic regulation in the treatment of hematological malignancy
Cao, H., Li, L., Xue, S., & Dai, H. (2022) · Hematological Oncology · doi:10.1002/hon.3088 · Cited by 47
Roca, M. S., Gennaro, E. D., & Budillon, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070912 · Cited by 45
Raucci, A., Zwergel, C., Valente, S., & Mai, A. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01677 · Cited by 43
Chitti, S., Srinivasarao, S., Reddy, P. S. K., Trivedi, P., Bobde, Y., Kumar, C., Rangan, K., Ghosh, B., & Sekhar, K. V. G. C. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.08.013 · Cited by 48
Self-citationRoutholla, G., Pulya, S., Patel, T., Abdul Amin, S., Adhikari, N., Biswas, S., Jha, T., & Ghosh, B. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105050 · Cited by 39
Self-citationThe role of acetylation and deacetylation in cancer metabolism
Wang, C., & Ma, X. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70145 · Cited by 32
“107”
Bruyer, A., Maes, K., Herviou, L., Kassambara, A., Seckinger, A., Cartron, G., Reme, T. X., Robert, N., Requirand, G., Boireau, S., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0025-x · Cited by 48
Matsuba, S., Niwa, S., Muraki, K., Kanatsuka, S., Nakazono, Y., Hatano, N., Fujii, M., Zhan, P., Suzuki, T., & Ohya, S. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.217315 · Cited by 40
Overview of class I HDAC modulators: Inhibitors and degraders
Huang, Z., Zeng, L., Cheng, B., & Li, D. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116696 · Cited by 34
Trivedi, P., Adhikari, N., Amin, S. A., Bobde, Y., Routholla, G., Jha, T., & Ghosh, B. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105046 · Cited by 45
Self-citationHe, P., Li, K., Li, S.-B., Hu, T., Guan, M., Sun, F., & Liu, W.-W. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4284 · Cited by 35
“Other data have also shown that HDAC3 modulates the JAK/STAT3 pathway in multiple myeloma cells (34).”
ResultSun, W., Zhang, N., Liu, B., Yang, J., Loers, G., Siebert, H., Wen, M., Zheng, X., Wang, Z., Han, J., et al. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00826 · Cited by 41
Amin, S. A., Adhikari, N., Kotagiri, S., Jha, T., & Ghosh, B. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.077 · Cited by 43
Self-citationZhang, L., Shan, X., Chen, Q., Xu, D., Fan, X., Yu, M., Yan, Q., & Liu, J. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28788 · Cited by 32
Lu, K., Fang, X., Feng, L., Jiang, Y., Zhou, X., Liu, X., Li, P., Chen, N., Ding, M., Wang, N., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.01.021 · Cited by 28
Iaconelli, J., Xuan, L. L., & Karmacharya, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071605 · Cited by 37
Recent advancement of HDAC inhibitors against breast cancer
Mehmood, S. A., Sahu, K. K., Sengupta, S., Partap, S., Karpoormath, R. V., Kumar, B., & Kumar, D. (2023) · Medical Oncology · doi:10.1007/s12032-023-02058-x · Cited by 34
“The deacetylation of lysine residues, which is associated with compacted chromatin, is known to impede transcription of the genes that are located in that region [83, 84].”
BackgroundTang, S., Cheng, B.-Q., Zhe, N., Ma, D., Xu, J.-B., Li, X.-Y., Guo, Y., Wu, W.-B., & Wang, J.-S. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000568 · Cited by 28
Zhang, M., Pan, Y., Tang, D., Dorfman, R. G., Xu, L., Zhou, Q., Zhou, L., Wang, Y., Yang, L., Yin, Y., et al. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0332-8 · Cited by 28
He, J., Chen, Q., Gu, H., Chen, J., Zhang, E., Guo, X., Huang, X., Yan, H., He, D., Yang, Y., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.181172 · Cited by 29
Ho, M., Chen, T., Liu, J., Dowling, P., Hideshima, T., Zhang, L., Morelli, E., Camci‐Unal, G., Wu, X., Tai, Y., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0493-x · Cited by 74
Self-citationHistone Deacetylase 3 Deletion in Mesenchymal Progenitor Cells Hinders Long Bone Development
Feigenson, M., Shull, L. C., Taylor, E. L., Camilleri, E. T., Riester, S. M., van Wijnen, A. J., Bradley, E. W., & Westendorf, J. J. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3236 · Cited by 28
The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay
Xia, J., Hu, H., Xue, W., Wang, X. S., & Wu, S. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1437156 · Cited by 24
Papavassiliou, K. A., & Papavassiliou, A. G. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.857401 · Cited by 26
“Isoform-selective HDACi may provide a better clinical benefit than pan-HDACi, while reducing or eliminating undesirable effects [2-5].”
BackgroundThe Role of Epigenetics in the Development and Progression of Multiple Myeloma
Ismail, N. H., Mussa, A., Zakaria, N. A., Al-Khreisat, M. J., Zahidin, M. A., Ramli, N. N., Mohammad, S. N. N. A., Hassan, R., Mohd Noor, N. H., Iberahim, S., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10112767 · Cited by 22
Targeted therapy for multiple myeloma: an overview on CD138-based strategies
Riccardi, F., Tangredi, C., Bo, M. D., & Toffoli, G. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1370854 · Cited by 23
“Similarly, histone acetylation modi fi ers have been found to have carcinogenic signi fi cance as they are involved in cell proliferation, survival and apoptosis (84 – 86).”
BackgroundContribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors
Chen, W.-C., Hu, G., & Hazlehurst, L. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.08.006 · Cited by 22
“Remarkably, romidepsin treatment decreases the expression of CD49d, a key component of the VAL-4 integrin that mediates the MM adhesion to stromal cells [71].”
BackgroundTahghighi, A., Seyedhashemi, E., Mohammadi, J., Moradi, A., Esmaeili, A., Pornour, M., Jafarifar, K., & Ganji, S. M. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01844-w · Cited by 21
“Benzamides like mocetinostat and entinostat are generally effective against class I HDACs [88].”
Wang, C., Shen, D., Hu, Y., Chen, J., Liu, J., Huang, Y., Yu, X., Chu, H., Zhang, C., Yin, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054805 · Cited by 26
“It also inhibits HDAC1 and HDAC2 with reduced potency [31].”
BackgroundSelf-citationJin, L., Zhu, L., Pan, Y., Fu, H., & Zhang, J. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.04.001 · Cited by 24
Designing potential HDAC3 inhibitors to improve memory and learning
Amin, S. A., Adhikari, N., Jha, T., & Ghosh, B. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1477625 · Cited by 28
Self-citationXu, X., Ding, Y., Jin, J., Xu, C., Hu, W., Wu, S., Ding, G., Cheng, R., Cao, L., & Jia, S. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01118-z · Cited by 23
“Because HDAC3 has been reported to regulate the phosphorylation of STAT3 Y705 in other cancer types [23, 24], we speculated that HDAC3 might influence the phosphorylation of STAT3 Y705 via activation of CDK1.”
BackgroundBülbül, E. F., Melesina, J., Ibrahim, H. S., Abdelsalam, M. A. M., Vecchio, A., Robaa, D., Zessin, M., Schutkowski, M., & Sippl, W. (2022) · Molecules · doi:10.3390/molecules27082526 · Cited by 19
“Then, protein–ligand complexes were minimized using the OPLS3e force-field to remove steric clashes [37].”
MethodLenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma
Sborov, D. W., Benson, D. M., Williams, N., Huang, Y., Bowers, M. A., Humphries, K., Efebera, Y. A., Devine, S. M., & Hofmeister, C. C. (2015) · British Journal of Haematology · doi:10.1111/bjh.13527 · Cited by 20
Novel hydroxamic acid derivative induces apoptosis and constrains autophagy in leukemic cells
Fischer, M. A., Mustafa, A. M., Hausmann, K., Ashry, R., Kansy, A. G., Liebl, M. C., Brachetti, C., Piée‐Staffa, A., Zessin, M., Ibrahim, H. S., et al. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.07.005 · Cited by 23
Bone Marrow Stroma-Induced Transcriptome and Regulome Signatures of Multiple Myeloma
Dziadowicz, S. A., Wang, L., Akhter, H., Aesoph, D., Sharma, T., Adjeroh, D., Hazlehurst, L., & Hu, G. (2022) · Cancers · doi:10.3390/cancers14040927 · Cited by 33
“Quinoline Consists of 1 H ‐1,2,3‐Triazole Hybrids: Design, Synthesis and Anticancer Evaluation”
Venkata, S. P. R. M., C.Narkhede, U., Jadhav, V., Naidu, C. G., Addada, R. R., Pulya, S., & Ghosh, B. (2019) · doi:10.1002/slct.201903938 · Cited by 19
Self-citationHDAC3 as an Emerging Therapeutic Target for Alzheimer's Disease and other Neurological Disorders
Li, Y., Izhar, T., & Kanekiyo, T. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04866-w · Cited by 19
“Both BG-45 and PT3 are benzamide class HDAC3 inhibitors [30, 31], but are less HDAC3 selective when compared to RGFP966 and BRD3308 (Table 1).”
Liang, H., Wang, Q., Wang, D., Zheng, H., Kalvakolanu, D. V., Lu, H., Wen, N., Chen, X., Xu, L., Ren, J., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114118 · Cited by 18
An epigenetic view of B‐cell disorders
Alberghini, F., Petrocelli, V., Rahmat, M., & Casola, S. S. (2015) · Immunology and Cell Biology · doi:10.1038/icb.2014.116 · Cited by 15
Hideshima, T., Mazitschek, R., Santo, L., Mimura, N., Görgün, G., Richardson, P. G. G., Raje, N. S., & Anderson, K. C. (2013) · Leukemia · doi:10.1038/leu.2013.301 · Cited by 16
Self-citationTargeting transcription factors in multiple myeloma: evolving therapeutic strategies
Li, S., Vallet, S., Sacco, A., Roccaro, A. M., Lentzsch, S., & Podar, K. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1605354 · Cited by 18
“Conversely, inhibition of HDAC3 by genetic knockdown or by the selective inhibitor BG45 abrogates MM cell proliferation [135].”
BackgroundGong, P., Li, K., Li, Y., Liu, D., Zhao, L., & Jing, Y. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0602-1 · Cited by 19
Epigenetic actions of environmental factors and promising drugs for cancer therapy (Review)
Bai, Z., Bai, B., Zhu, J., Di, C., Li, X., & Zhou, W. (2017) · Oncology Letters · doi:10.3892/ol.2017.7597 · Cited by 11
“A previous study revealed that HDACs serve roles as crucial mediators in tumor survival and progression (43).”
Hasan, S., Cassinat, B., Droin, N., Couédic, J. L., Favale, F., Monte-Mór, B., Lacout, C., Fontenay, M., Dosquet, C., Chomienne, C., et al. (2014) · Leukemia · doi:10.1038/leu.2013.303 · Cited by 17
Pattanayak, P., Nikhitha, S., Halder, D., Ghosh, B., & Chatterjee, T. (2024) · RSC Advances · doi:10.1039/d4ra02856b · Cited by 16
Self-citationChang, S., Hsieh, R., Huang, K., Chang, C. A., Chiu, F., Kuo, H., Chen, C., & Su, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144252 · Cited by 18
Medicinal chemistry advances in targeting class I histone deacetylases
Abdallah, D. I., de Araujo, E. D., Patel, N. H., Hasan, L. S., Moriggl, R., Krämer, O. H., & Gunning, P. T. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00166 · Cited by 17
“Finally, a cap-less inhibitor, BG45, bears a pyrazine linker, which allows for faster kinetics of binding to the target protein due to the rigidity of the molecule and lack of degrees of freedom that comes with a cap group [65].”
BackgroundCross, J. M., Coulson, M. E., Smalley, J. P., Pytel, W. A., Ismail, O., Trory, J. S., Cowley, S. M., & Hodgkinson, J. T. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00199c · Cited by 27
Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors
Driscoll, J. J., & Brailey, M. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9698-5 · Cited by 16
Down-regulation of HDAC3 inhibits growth of cholangiocarcinoma by inducing apoptosis
Zhang, M., Yin, Y., Dorfman, R. G., Zou, T., Pan, Y., Li, Y., Wang, Y., Zhou, Q., Zhou, L., Kong, B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19660 · Cited by 18
Coregulator profiling of the glucocorticoid receptor in lymphoid malignancies
Clarisse, D., Thommis, J., Wesemael, K. V., Houtman, R., Ratman, D., Tavernier, J. H., Offner, F. C., Beck, I. M. E., & Bosscher, K. D. (2017) · Oncotarget · doi:10.18632/oncotarget.22764 · Cited by 14
Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors
Grumetti, L., Lombardi, R., Iannelli, F., Pucci, B., Avallone, A., Gennaro, E. D., & Budillon, A. (2022) · Cancers · doi:10.3390/cancers14030695 · Cited by 16
Hamoud, M. M. S., Pulya, S., Osman, N. A., Bobde, Y., Hassan, A. E. A., Abdel‐Fattah, H. A., Ghosh, B., & Ghanim, A. M. (2020) · New Journal of Chemistry · doi:10.1039/d0nj01274b · Cited by 25
Self-citationJin, Z., Zhou, S.-J., Zhang, Y., Ye, H.-G., Jiang, S.-F., Yu, K., & Ma, Y.-Y. (2016) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2016.10.069 · Cited by 13
Łowicki, D., & Przybylski, P. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118213 · Cited by 14
Himaja, A., Routholla, G., Patel, T. K., Banerjee, S., Begum, D., Regula, S., Pulya, S., Biswas, S., Adhikari, N., & Ghosh, B. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117636 · Cited by 12
Self-citation
Metadata
- Authors
- Minami, J., Suzuki, R., Mazitschek, R., Gorgun, G., Ghosh, B., Cirstea, D., Hu, Y., Mimura, N., Ohguchi, H., Cottini, F., Jakubikova, J., Munshi, N. C., Haggarty, S. J., Richardson, P. G., Hideshima, T., & Anderson, K. C.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Anderson, K C
- ORCID
- Venue
- Leukemia
- Published
- 2013-08-05
- Volume
- 28
- Issue
- 3
- Pages
- 680-689
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- PMC
- PMC4165599
- OpenAlex
- W2004288940
- Cited by
- 159
- References
- 37
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 11 · 2023: 15 · 2022: 15 · 2021: 10 · 2020: 15 · 2019: 13 · 2018: 14 · 2017: 16 · 2016: 6 · 2015: 18 · 2014: 8 · 2013: 3
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5p01ca078378-15, 5r01ca178264-05)
- U.S. Public Health Service (P50100707)
- National Institute on Drug Abuse (R01 DA02830)
- National Cancer Institute (R01-CA178264, P01-CA-78378, P50CA086355, R01- CA50947, P01-CA078378, P50CA100707, R01CA050947, P01CA155258)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Keywords
- HDAC3, multiple myeloma, HDAC3 inhibitors, STAT3 phosphorylation, STAT3 acetylation, bortezomib combination therapy, apoptosis, caspase activation, poly(ADP-ribose) polymerase, interleukin-6, mesenchymal stem cells, HDAC isoform selectivity, tumor growth inhibition
- MeSH terms
- Histone Deacetylase 3, Cell Division, Histone Deacetylases, Humans, Multiple Myeloma, Cell Line, Tumor, Gene Knockdown Techniques, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
